The global problem of antibiotic resistance

Critical Reviews in Immunology

Volumn 30, Issue 1, 2010, Pages 79-93

  Gootz, Thomas D ^a  

^a Deep River   (United States)

Author keywords

Acinetobacter; Antimicrobial therapy; Klebsiella; Methicillin resistant; Staphylococcus aureus

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; METICILLIN; OUTER MEMBRANE PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL GENE; BACTERIAL INFECTION; GENE INACTIVATION; GENE INSERTION; HUMAN; INTEGRON; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIDRUG RESISTANCE; PLASMID; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; TRANSPOSON; BACTERIA; DRUG EFFECTS; HEALTH; INTERNATIONAL COOPERATION; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, MICROBIAL; GLOBAL HEALTH; HUMANS; INTERNATIONALITY;

EID: 77951006116     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevimmunol.v30.i1.60     Document Type: Review

References (96)

1. IMS Global Pharmaceutical Market Forecast, 2008. IMS Health, Plymouth Meeting, PA
2. Hidron AI, Edwards JR, Patel J, Horon TC, Sievert DM, Pollock DA, Fridkin SK. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to national healthcare safety network at the centers for disease control and prevention, 2006-2007. Infect Cont Hosp Epidem. 2008; 29(11):996-1011.
3. Cardo D, Horan T, Andrus M, Dembinski M, Edwards J, Peavey G, Tolson J, Wagner D. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470-485.
4. Mingeot-Leclercq M-P, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother. 1999;43:727-737.
5. Li Zhang X-Z, McKay GA, Poole K. Role of the acetyltransferase AAC(6)-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas malto-philia. J Antimicrob Chemother. 2003;51:803-811.
6. Poole K. Aminnoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49: 479-487.
7. Li X-Z, Poole K, Nikaido H. Contributions of MexAB-OprM; an EmrE homolog to intrinsic resistance of Pseudomonas aeruginosa to aminoglycosides and dyes. Antimicrob Agents Chemother. 2003;47:27-33.
8. Chevalier J, Bredin J, Mahamoud A, Mallea M, Barbe J, Pages J-M. Inhibitors of antibiotic efux in resistant Enterobacter aerogenes and Klebsiella pneumoniae strains. Antimicrob Agents Chemother. 2004;48:1043-1046.
9. Poole K. Efux-mediated multiresistance in gram-negative bacteria. Clin Microbiol Infect. 2004;10:12-26.
10. Li X-Z, Nikaido H. Efux-mediated drug resistance in bacteria. Drugs. 2004;64:159-204.
11. Poole K. Outer membranes and efux: the path to multidrug resistance in gram-negative bacteria. Curr Pharm Biotech. 2002;3:77-98.
12. Duncan L, Doyle T, Du Q, Ehrhardt J, Lynch AS, Mdluli K, Robertson GT. Construction of a novel Pseudomonas aeruginosa strain panel defcient in fifty-two potential drug efflux systems. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 30 Oct-2 Nov, 2004.
13. Baucheron S, Imverechts H, Chaslus-Dancla E, Cloeckaert A. Te AcrAB multidrug transporter plays a major role in high-level fuoroquinolone resistance in Salmonella enterica serovar typhimurium phage type DT204. Microb Drug Res. 2002;8:281-289.
14. Lomovskaya O, Lee A, Hoshino K, Ishida H, Mistry A, Warren MS, Boyer E, Chamberland S, Lee VJ. Use of a genetic approach to evaluate the consequences of inhibition of efux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1999;43:1340-1346.
15. Oethinger M, Dern WV, Jellen-Ritter AS, McMurry LM, Levy SB. Inefectiveness of topoisomerase mutations in mediating clinically signifcant fuoroquinolone resistance in Escherichia coli in the absence of the acrAB efux pump. Antimicrob Agents Chemother. 2000;44:10-13.
16. Okamoto K, Gotoh N, Nishino T. Pseudomonas aerugi-nosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay. Antimicrob Agents Chemother. 2001;45:1964-1971.
17. Vialli MA, Murphy E, Projean SJ, Bradford PA. AcrAB multidrug efux pump is associated with reduced levels of susceptibility to tigecycline (gar-936) in Proteus mirabilis. Antimicrob Agents Chemother. 2003;47:665-669.
18. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, gar-936 tested against 1,203 recent clinical isolates. Diagn Microbiol Infect Dis. 2000;36:19-36.
19. Vila J, Marti S, Sanchez-Cespedes J. Porins, efux pumps and multidrug resistance in Acinetobacter bau-mannii. J Antimicrob Chemother. 2007;59:1210-1215.
20. Gribun A, Nitzan Y, Pechatnikov IH, G., Katcof DJ. Molecular and structural characterization of the HMP-AB gene encoding a pore-forming protein from a clinical isolate of Acinetobacter baumannii. Curr Microbiol. 2003;47(5):434-443.
21. Siroy A, Molle V, Lemaître-Guillier C, Vallenet D, Pestel-Caron M, Cozzone AJ, Jouenne T, Dé E. Channel formation by CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii. Antimicrob Agents Chemother. 2005;49(12): 4876-4883.
22. Mussi MA, Limansky AS, Viale A. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins. Antimicrob Agents Chemother. 2005;49(4): 1432-1440.
23. Gootz TD, Marra A. Acinetobacter baumannii: an emerging multidrug-resistant threat. Expert Rev Anti Infect Ter. 2008;6(3):309-325.
24. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents and Chemother. 2001;45(12):3375-3380.
25. Marchand I, Damier-Piolle L, Courvalin P, Lambert T. Expression of the RND-type efux pump AdeABD in Acinetobacter baumannii is regulated by the AdeRS two component system. Antimicrob Agents Chemother. 2004;48(9):3298-3304.
26. Piddock LJV. Clinically relevant chromosomally encoded multidrug resistance efux pumps in bacteria. Clin Microbiol Rev. 2006;19(2):382-402.
27. Ruzin A, Keeney D, Bradford PA. AdeABC multidrug efux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother. 2007;59:1001-1004.
28. Peleg AY, Adams J, Paterson DL. Tigecycline efux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51: 2065-2069.
29. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacother. 2007;27(8):1198-1201.
30. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, Husain S, Kwak EJ, Bhat SV, Paterson DL. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother. 2007;59:128-131.
31. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecy-cline resistance in multidrug resistant Acinetobacter bau-mannii. J Antimicrob Chemother. 2007;59:772-774.
32. Nummila, K Kilpelainen I, Zahringer U, Vaara M, Helander IM. Lipopolysaccharides of polymyxin B-resistant mutants of Escherichia coli are extensively substituted by 2-aminoethyl pyrophosphate and contain aminoarabinose in lipid A. Mol Microbiol. 1995;16:271-278.
33. 31P-NMR study. Mol Microbiol. 1994;11:481-487.
34. Kaca W, Radziejewska-Lebrecht J, Bhat UR. Efect of polymyxins on the lipopolysaccharide-defective mutants of Proteus mirabilis. Microbios. 1990;61: 23-32.
35. Macfarlane EL, Kwasnicka A, Hancock RE. Role of Pseudomonas aeruginosa phoP-phoQ in resistance to antimicrobial cation peptides and aminoglycosides. Microbiology. 2000;146:2543-2554.
36. Achouak W, Heulin T, Pages JM. Multiple facets of bacterial porins. FEMS Microbiol Lett 2001;199:1-7.
37. Weindorf H, Schmidt H, Martin HH. Contribution of overproduced chromosomal ß-lactamase and defective outer membrane porins to resistance to extended-spectrum ß-lactam antibiotics in Serratia marcescens. J Antimicrob Chemother. 1998;41:189-195.
38. Domenech-Sanchez A, Hernandez-Alles S, Martinez-Martinez L, Benedi VJ, Alberti S. Identifcation and characterization of a new porin gene of Klebsiella pneumoniae: its role in ß-lactam antibiotic resistance. J Bacteriol. 1999;181:2726-2732.
39. Cornaglia G, Russell K, Satta G, Fontana R. Relative importances of outer membrane permeability and group 1 ß-lactamase as determinants of meropenem and imipenem activities against Enterobacter cloacae. Antimicrob Agents Chemother. 1995;39:350-355.
40. TEM-1 variants:their role in ß-lactam resistance in Klebsiella pneumoniae. J Antimicrob Chemother. 2003;52:899-903.
41. Jacoby GA, Mills DM, Chow N. Role of ß-lactamases and porins in resistance to ertapenem and other ß-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004;48:3203-3206.
42. Crowley B, Benedi VJ, Domenech-Sanchez A. Expression of SHV-2 ß-lactamase and reduced amounts of ompk36 porin in Klebsiella pneumoniae results in increased resistance to cephalosporins and carbapenems. Antimicrob Agents Chemother. 2002;46:3679-3682.
43. Pai H, Kim J-W, Kim J, Hyang Lee J, Won Choe K, Gotoh N. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2001;45:480-484.
44. Yigit H, Anderson GJ, Biddle JW, Steward CD, Rasheed JK, Valera LL, McGowan Jr JE, Tenover FC. Carbapenem resistance in a clinical isolate of Enterobacter aerogenes is associated with decreased expression of ompF and ompC porin analogs. Antimicrob Agents Chemother. 2002;46:3817-3822.
45. Esterling L, Delihas N. Te regulatory RNA gene micF is present in several species of gram-negative bacteria and is phylogenetically conserved. Molec Micro. 1994;12:839-846.
46. Delihas N, Forst S. MicF: an antisense RNA gene involved in response of Escherichia coli to global stress factors. J Mol Biol. 2001;313:1-12.
47. George AM, Levy SB. Gene in the major cotrans-duction gap of the Escherichia coli K-12 linkage map required for the expression of chromosomal resistance to tetracycline and other antibiotics. J Bacteriol. 1983;155:541-548.
48. Barbosa, TM, Levy S. Diferential expression of over 60 chromosomal genes in Escherichia coli by constitutive expression of marA. J Bacteriol 2000;182:3467-3474.
49. Lee E-H, Collatz E, Podglajen I, Gutmann L. A rob-like gene of Enterobacter cloacae afecting porin synthesis and susceptibility to multiple antibiotics. Antimicrob Agents Chemother. 1996;40:2029-2033.
50. Simonet V, Mallea M, Pages J-M. Substitutions in the eyelet region disrupt cefepime difusion through the Escherichia coli ompF channel. Antimicrob Agents Chemother. 2000;44:311-315.
51. Hernandez-Alles S, Bened VJ, Marinez-Martinez L, Pascual A, Aguilar A, Tomas JM, Alberti S. Development of resistance during antimicrobial therapy caused by insertion sequence interruption of porin genes. Antimicrob Agents Chemother. 1999;43:937-939.
52. Bush K, Jacoby GA, Medeiros AA. A functional classifcation scheme for ß-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995;39:1211-1233.
53. st century: characterization, epidemiology and detection of this important resistance threat. Clin Microbiol Revs. 2001;14:933-951.
54. Philippon A, Arlret G, Jacoby GA. Plasmid-determined ampC-type ß-lactamases. Antimicrob Agents Chemother. 2002;46:1-11.
55. Gootz, TD. Global dissemination of ß-lactamases mediating resistance to cephalosporins and carbap-enems. Expert Rev Antiinfect Ter. 2004;2:317-327.
56. Fisher JF, Meroueh SO, Mobashery S. Bacterial resistance to ß-lactam antibiotics:compelling opportunism, compelling opportunity. Chem Rev. 2005;105:395-424.
57. Bush K, Jacoby G. Amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor-resistant ß-lactamases. Lahey clinic website (Accessed March 2010). www.lahey.org/studies/webt.htm.
58. Bonnet R. Growing group of extended-spectrum ß-lactamases:the CTX-M enzymes. Antimicrob Agents Chemother. 2004;48:1-14.
59. Livermore DM. Bacterial resistance: origins, epidemiology and impact. Clin Infect Dis. 2003;36(Suppl 1):S11-23.
60. Wedhagen GF, Poirel L, Nordmann P. Ambler class A extended-spectrum ß-lactamases in Pseudomonas areuginosa: novel developments and clinical impact. Antimicrob Agents Chemother. 2003;47:2385-2392.
61. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units. JAMA. 2003;289:885-888.
62. Dudley, M. Enterobacteriaceae working group; Subcommittee on antimicrobial susceptibility testing. AST meeting book 1. Clinical and Laboratory Standards Institute, Tampa, FL, 9-11 Jan 2005, Tampa, FL.
63. Hanson ND, Tomson KS, Smith Moland E, Sanders CC, Gerhold G, Penn RG. Molecular characterization of a multiply resistant Klebsiella pneumoniae encoding ESBLs and a plasmid-mediated AmpC. J Antimicrob Chemother. 1999;44:377-380.
64. Liebana E, Batchelor M, Clifton-Hadley FA, Davies RH, Hopkins KL, Trelfall EJ. First report of Salmonella isolates with the DHA-1 AmpC ß-lactamase in the United Kingdom. Antimicrob Agents Chemother. 2004;48: 4492.
65. MIR-1. Antimicrob Agents Chemother. 2004;48:4177-4182.
66. Literacka E, Empel J, Baraniak A, Sadowy E, Hryniewicz W, Gniadkowski M. Four variants of the Citrobacter freundii ampC-type cephalosporinases, including novel enzymes CMY-14 and CMY-15, in a Proteus mira-bilis clone widespread in Poland. Antimicrob Agents Chemother. 2004;48:4136-4143.
67. Park Y-J, Park SY, Oh E-J, Park J-J, Lee K-Y, Woo G-J, Lee K. Occurrence of extended-spectrum ß-lactamases among chromosomal ampC-producing Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens in Korea and investigation of screening criteria. Diagn Microbiol Infect Dis. 2005;51:265-269.
68. Nordmann P, Poirel L. Emerging carbapenemases in gram-negative aerobes. Clin Microbiol Infect. 2002;8:321-331.
69. Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, Rahal JJ, Brooks S, Cebular S, Quale J. Emergence of carbapenem-resistant Klebsiella pneu-moniae species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 ß-lactamases in New York City. Clin Infect Dis. 2004;39:55-60.
70. Woodford N, Tierno PM Jr., Young K, Tysall L, Papelou MFI, Ward E, Painter RE, Suber DF, Shungu D, Silver LL, Inglima K, Kornblum J, Livermore DM. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A ß-lactamase KPC-3, in a New York City medical center. Antimicrob Agents Chemother. 2004;48:4793-4799.
71. Yigit H, Queenan AM, Rasheed K, Biddle JW, Donenech-Sanchez A, Alberti S, Bush K, Tenover FC. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing ß-lactamase KPC-2. Antimicrob Agents Chemother 2003;47:3881-3889.
72. KPC gene. Antimicrob Agents Chemother. 2008;52:1257-1263.
73. KPC carbapenemase genes on plasmids from Klebsiella pneumoniae strains isolated in a New York City hospital. Antimicrob Agents Chemother. 2009;53:1998-2004.
74. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-ß-lactamases: the quiet before the storm? Clin Microbiol Rev. 2005;18:306-325.
75. IMP-16, and a fused form of amin-oglycoside-resistant gene aac(6)-30/aac(6)-Ib:report from the sentry antimicrobial surveillance program. Antimicrob Agents Chemother. 2004;48:4693-4702.
76. Giakkoupi P, Xanthaki A, Kanelopoulou M, Vlahaki A, Miriagou V, Kontou S, Papafraggas E, Malamou-Lada H, Tzouvelekis LS, Legakis NJ, Vatopoulos AC. VIM-1 metallo-ß-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J Clin Microbiol. 2003;41:3893-3896.
77. Yan J-J, Ko W-C, Chuang C-L, Wu J-J. Metallo-ß-lactamase-producing Enterobacteriaceae isolates in a university hospital in Taiwan: prevalence of IMP-8 in Enterobacter cloacae and frst identifcation of VIM-2 in Citrobacter freundii. J Antimicrob Chemother. 2002;50:503-511.
78. GIM-1, encoding a new subclass of metallo-ß-lactamase. Antimicrob Agents Chemother. 2004;48:4654-4661.
79. Doménech-Sánchez A, Martínez-Martínez L, Hernández-Allés S, del Carmen Conejo M, Pascual A, Tomás JM, Albertí S, Benedí VJ. Role of Klebsiella pneumoniae ompk35 porin in antimicrobial resistance. Antimicrob Agents Chemother. 2003;47:3332-3335.
80. Rasheed JK, Anderson GJ, Yigit H, Queenan AM, Doménech- Sánchez A, Swenson JM, Biddle JW, Ferraro MJ, Jacoby GA, Tenover FC. Characterization of the extended-spectrum ß-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18. Antimicrob Agents Chemother. 2000;44:2382-2388.
81. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumo-niae is associated with the combination of ACT-1, a plasmid-mediated ampC ß-lactamase, and the loss of an outer membrane protein. Antimicrob Agents Chemother. 1997;41:563-569.
82. Poirel L, Hertitier C, Tolun V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004;48:15-22.
83. ACT-1 β-lactamase production, porin ompk35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoE. Antimicrob Agents Chemother. 2006;50:3396-3406.
84. S on the expression of the pho regulon genes of Escherichia coli. Microbiol. 2004;150:2985-2992.
85. Gorwitz, RJ, Kruszon-Moran, D, McAllister K, McQuillan g, McDougal LK, Fosheim GE, Jensen BJ, Killgore G, Tenover FC, Keuhnert MJ. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. JID 2008;197:1226-1234.
86. Ratnaraja, N, Hawkey P. Current challenges in treating MRSA: what are the options? Expert Rev Anti Infect Ter. 2008;6(5):601-618.
87. Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EM, Gemmell CG, Kim MN, Ploy MC, El-Sohh N, Ferraz V, Hiramatsu K. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol. 2003;41:5-14.
88. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentratin creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis. 2006;42(Suppl 1): S13-24.
89. Lodise T P, Graves J, Evans A, Grafuner E, Helmecke M, Lomaestro BM, Stellrecht K. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacter-emia treated with vancomycin. Antimicrob Agents Chemother. 2008;52:3315-3320.
90. Perichon B, Courvalin P. Heterologous expression of the enterococcal vanA operon in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2004;48:4281-4285.
91. Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, Flanagan SE, Kolonay JF, Shetty J, Killgore GE, Tenover FC. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science. 2003;302:1569-1571.
92. Zhu W, Clark NC, McDougal LK, Hageman J, McDonald LC, Patel JB. Vancomycin-resistant Staphylococcus aureus isolates associated with Inc-like vanA plasmids in Michigan. Antimicrob Agents Chemother. 2008;52:452-457.
93. Foucault, M-L, Courvalin P, Grillot-Courvalin C. Fitness cost of vanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53:2354-2359.
94. Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B. Te cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother. 2006;50:2500-2505.
95. Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother. 2008;52:2244-2246.
96. Shaw KJ, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar CM, Shinabarger D, Zurenko G. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother. 2008;52:4442-4447.